Impact of a reduced dosing interval of lanreotide autogel (LAN) on tumor growth rate (TGR) in patients with progressive neuroendocrine tumors (NETs) in the prospective, single-arm, phase 2 CLARINET FORTE trial
Dromain C, Cwikla JB, Lombard-Bohas C, Borbath , Shah T, Pape UF, Capdevila J, Panzuto F, Ruszniewski P, Thanh TXM, Houchard A, Pavel ME (2022)
Publication Type: Conference contribution
Publication year: 2022
Journal
Publisher: WILEY
City/Town: HOBOKEN
Pages Range: 105-105
Conference Proceedings Title: JOURNAL OF NEUROENDOCRINOLOGY
Authors with CRIS profile
Involved external institutions
Lausanne University Hospital / Centre hospitalier universitaire vaudois (CHUV)
Switzerland (CH)
University of Warmia and Mazury in Olsztyn
Poland (PL)
Cliniques universitaires Saint-Luc (CHU St-Luc)
Belgium (BE)
Queen Elizabeth Hospital
United Kingdom (GB)
Asklepios Klinik St. Georg
Germany (DE)
Vall d'Hebron University Hospital / Hospital Universitari Vall d'Hebron
Spain (ES)
Azienda ospedaliera Sant'Andrea
Italy (IT)
University of Paris 4 - Paris-Sorbonne / Université paris IV Paris-Sorbonne
France (FR)
Ipsen Pharma
France (FR)
Hôpital Edouard Herriot
France (FR)
Switzerland (CH)
University of Warmia and Mazury in Olsztyn
Poland (PL)
Cliniques universitaires Saint-Luc (CHU St-Luc)
Belgium (BE)
Queen Elizabeth Hospital
United Kingdom (GB)
Asklepios Klinik St. Georg
Germany (DE)
Vall d'Hebron University Hospital / Hospital Universitari Vall d'Hebron
Spain (ES)
Azienda ospedaliera Sant'Andrea
Italy (IT)
University of Paris 4 - Paris-Sorbonne / Université paris IV Paris-Sorbonne
France (FR)
Ipsen Pharma
France (FR)
Hôpital Edouard Herriot
France (FR)
How to cite
APA:
Dromain, C., Cwikla, J.B., Lombard-Bohas, C., Borbath, ., Shah, T., Pape, U.F.,... Pavel, M.E. (2022). Impact of a reduced dosing interval of lanreotide autogel (LAN) on tumor growth rate (TGR) in patients with progressive neuroendocrine tumors (NETs) in the prospective, single-arm, phase 2 CLARINET FORTE trial. In JOURNAL OF NEUROENDOCRINOLOGY (pp. 105-105). HOBOKEN: WILEY.
MLA:
Dromain, C., et al. "Impact of a reduced dosing interval of lanreotide autogel (LAN) on tumor growth rate (TGR) in patients with progressive neuroendocrine tumors (NETs) in the prospective, single-arm, phase 2 CLARINET FORTE trial." Proceedings of the JOURNAL OF NEUROENDOCRINOLOGY HOBOKEN: WILEY, 2022. 105-105.
BibTeX: Download